This time, the FDA took issue with how the ad positioned Ozempic as superior to other GLP-1s, taking aim at small details from comedic devices to the color of shirts.

The U.S. Food and Drug Administration (FDA) has issued warning letters to 30 telehealth companies citing false or misleading claims about compounded GLP-1 weight-loss products on their websites. The ...

Submit an appeal, even if you’re worried you’ll lose. Yaver said that, based on the research set to be published in her book, Coverage Denied: How Health Insurers Drive Inequality in the United States ...

Rare disease drug approval frustrations grow; MAHA offshoot grows in Europe; Eli Lilly is still on track to launch its oral obesity drug in Q2.

In recent years, several states have opted to expand the coverage offered by their Medicaid programs, seeking to boost access in recognition of its importance to overall health.

Partnering with Ogilvy and GCI Health, BI’s Beyond the Scars campaign leverages the actress’s personal caregiver journey to help patients identify interstitial lung disease sooner.

Using a copay card has gotten trickier as insurers push back. First, patients need to understand whether there is an annual dollar or time limit on the card and how it works with their insurance.

Trump’s MFN pricing includes an unannounced expiration date; U.S. Surgeon General nominee faces scrutiny from some Republicans; U.S. science agencies experience funding hiccup.

The imbalance between pharma’s investment in brand advertising versus corporate and public affairs has become a strategic liability amid the most challenging regulatory conditions the drug industry ...

The imbalance between pharma’s investment in brand advertising versus corporate and public affairs has become a strategic liability amid the most challenging regulatory conditions the drug industry ...

Sanofi has established a robust presence in New England, employing about 5,000 workers based in Massachusetts.

FDA to incentivize quick reviews; Generate Biomedicines raises $400M in IPO; No­var­tis, Take­da agree to en­ter third round of Medicare drug price ne­go­ti­a­tions.